Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531

Blood. 2017 Aug 17;130(7):943-945. doi: 10.1182/blood-2017-01-762336. Epub 2017 Jul 3.
No abstract available

Publication types

  • Letter
  • Meta-Analysis
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoglycosides / administration & dosage
  • Aminoglycosides / adverse effects
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Clinical Trials, Phase III as Topic / statistics & numerical data*
  • Female
  • Follow-Up Studies
  • Gemtuzumab
  • Hepatic Veno-Occlusive Disease / chemically induced
  • Humans
  • Infant
  • Kaplan-Meier Estimate
  • Male
  • Multicenter Studies as Topic / statistics & numerical data*
  • Pilot Projects
  • Proportional Hazards Models
  • Randomized Controlled Trials as Topic / statistics & numerical data*
  • Remission Induction
  • Treatment Outcome

Substances

  • Aminoglycosides
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Gemtuzumab